Published in Virus Weekly, September 1st, 2009
An analysis of the adverse events reported following distribution of quadrivalent human papillomavirus recombinant vaccine since 2006 indicates that adverse event rates were consistent with pre-licensing data and expected background rates of other vaccines, with the exception of a higher proportion of reports of fainting and blood clots, according to a study in the August 19 issue of JAMA.
In June 2006 the Food and Drug Administration (FDA) licensed the quadrivalent human papillomavirus recombinant vaccine (qHPV) for females age 9 to 26 years to prevent infection with genital human papillomavirus (HPV) types 6,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Virus Weekly
Source: Virus Weekly (2009-09-01)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.